

Corporation obtaining approval, the name of its representative, and the address of its main office

Name: Zoetis Japan Inc.

Applicant: Jorge Perez-Martinez, President & CEO      seal

Address: 3-22-7, Yoyogi, Shibuya-ku, Tokyo

Approved Type 1 Use Regulation

Name of the type of Living Modified Organism:	<i>aroA</i> gene deleted avian <i>E.coli</i> strain EC34195 (Poulvac <i>E.coli</i> ) ( <i>Escherichia coli</i> )
Content of the Type 1 Use of Living Modified Organism:	<p>[1] Transportation and storage (including transportation and storage of animals inoculated with genetically modified active live vaccine)</p> <p>[2] When falling under the category of trial aiming to gather materials related to the results of clinical test (hereinafter referred to as “clinical trial”) among the materials that shall be submitted by the provisions of Article 14, Paragraph 3 of the Pharmaceutical Affairs Act (Act No. 145 of 1960; PAA), use in accordance with a notification of clinical trial plan submitted based on Article 80-2, Paragraph 2 of PAA and a trial implementation protocol prepared based on Article 7 of the Ordinance for Good Clinical Practice of New Animal Drugs (Ordinance of the Ministry of Agriculture, Forestry and Fisheries No.75 of 1997)</p> <p>[3] Use in accordance with the approval application based on Article 14, Paragraph 1 of PAA (excluding acts that fall under [4] below)</p> <p>[4] Inoculation (inoculation to chicken)</p> <p>[5] Disposal of instruments and residues after inoculation in accordance with the disposal standards for infectious industrial waste stipulated by Article 12-2 of the Waste Management and Public Cleansing Act (Act No.137 of 1970)</p> <p>[6] Disposal that does not fall under [5] above (including the cases that involve with disposal of animals inoculated with genetically modified active live vaccine)</p> <p>[7] Acts incidental to [1] to [6] above</p>
Method of the Type 1 Use of Living Modified Organism:	—